However, they can jump-start progress and make it easier for patients to adopt healthier lifestyles by reducing appetite and improving energy, which can be a virtuous cycle
Embracing the pros and cons of the new weight loss medications (semaglutide, tirzepatide, etc.)
The continued use of unregulated agents like melanotan I and II is particularly concerning
CMS Extends Medicares Short-Term Bridge Program for GLP-1 Obesity Drug Coverage The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare, called the BALANCE model, will not launch as scheduled on January 1, 2027
Another issue with AFS, difficulty in losing weight, especially around the middle of the body, may get a helpful boost with this peptide